Back to Search Start Over

Tumor Size Is Not Everything: Advancing Radiomics as a Precision Medicine Biomarker in Oncology Drug Development and Clinical Care. A Report of a Multidisciplinary Workshop Coordinated by the RECIST Working Group.

Authors :
Nakajima, Erica C.
Simpson, Amber
Bogaerts, Jan
de Vries, Elisabeth G.E.
Do, Richard
Garalda, Elena
Goldmacher, Greg
Kinahan, Paul E.
Lambin, Philippe
LeStage, Barbara
Li, Qin
Lin, Frank
Litière, Saskia
Perez-Lopez, Raquel
Petrick, Nicholas
Schwartz, Lawrence
Seymour, Lesley
Shankar, Lalitha
Laurie, Scott A.
Source :
JCO Precision Oncology; 5/9/2024, p1-8, 8p
Publication Year :
2024

Abstract

Radiomics, the science of extracting quantifiable data from routine medical images, is a powerful tool that has many potential applications in oncology. The Response Evaluation Criteria in Solid Tumors Working Group (RWG) held a workshop in May 2022, which brought together various stakeholders to discuss the potential role of radiomics in oncology drug development and clinical trials, particularly with respect to response assessment. This article summarizes the results of that workshop, reviewing radiomics for the practicing oncologist and highlighting the work that needs to be done to move forward the incorporation of radiomics into clinical trials. This paper by the RECIST Working Group outlines a path to realize the potential of radiomics as a precision biomarker. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
24734284
Database :
Complementary Index
Journal :
JCO Precision Oncology
Publication Type :
Academic Journal
Accession number :
177153247
Full Text :
https://doi.org/10.1200/PO.23.00687